Country: Malta
Language: English
Source: Medicines Authority
Viatris Healthcare Limited Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN , Ireland
M01AE01
IBUPROFEN 800 mg
PROLONGED-RELEASE TABLET
IBUPROFEN 800 mg
POM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
Authorised
2019-04-10
Page 1 of 9 PACKAGE LEAFLET: INFORMATION FOR THE USER BRUFEN RETARD 800 MG PROLONGED-RELEASE TABLETS ibuprofen READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET : 1. What Brufen Retard is and what it is used for 2. What you need to know before you take Brufen Retard 3. How to take Brufen Retard 4. Possible side effects 5. How to store Brufen Retard 6. Contents of the pack and other information 1. WHAT BRUFEN RETARD IS AND WHAT IT IS USED FOR Brufen Retard contains the active substance ibuprofen and belongs to a group of medicines called NSAIDs (non-steroidal anti-inflammatory drugs). Brufen Retard relieves pain, reduces fever and has an anti-inflammatory effect. Brufen Retard is used for symptomatic treatment of pain and inflammation in rheumatic conditions (rheumatoid arthritis and osteoarthritis) in adults and adolescents (12-18 years old, 40 kg and above). 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE BRUFEN RETARD DO NOT TAKE BRUFEN RETARD: - if you are allergic to ibuprofen or any of the other ingredients of this medicine (listed in section 6). - if you have stomach ulcer or duodenal ulcer or have had recurrent ulcer or bleeding in the stomach or intestine - if you have severe liver or kidney disease - if you have severe heart failure - if you have an increased tendency to bleed - if you previously have had bleeding or perforation in your stomach or intestine when treated with Brufen Retard or a similar product (other NSAIDs) - if you are in the last three months of pregnancy - if you have experienced all Read the complete document
Page 1 of 13 S UMMARY OF P RODUCT C HARACTERISTICS 1 N AME OF THE M EDICINAL P RODUCT Brufen Retard 800 mg prolonged-release tablets. 2 Q UALITATIVE AND Q UANTITATIVE C OMPOSITION One tablet contains 800 mg ibuprofen. For the full list of excipients, see section 6.1. 3 P HARMACEUTICAL F ORM Prolonged-release tablet White, oval, about 21x10 mm, film-coated tablet. 4 C LINICAL P ARTICULARS 4.1 THERAPEUTIC INDICATIONS Brufen Retard is indicated in adults and adolescents Symptomatic treatment of pain and inflammation in rheumatoid arthritis and osteoarthritis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Treatment should start with the lowest dose anticipated to be effective, which can subsequently be adjusted, depending on the therapeutic response and any adverse reactions. In long-term treatment a low maintenance dose should be the aim. The risk of adverse reactions may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). _Adults and adolescents older than 12 years (≥ 40 kg): _ 2 tablets in the evening. May be increased to maximum 3 tablets daily, divided between morning and evening. The maximum dose in a 24-hour period is 2,400 mg. The tablets should be _swallowed whole _ with at least half a glass of water. Patients who have suffered dyspepsia or gastrointestinal bleeding when taking other oral antiphlogistic drugs have tolerated ibuprofen well, but should be monitored regularly the first time they are treated with Brufen Retard. PAEDIATRIC POPULATION Brufen Retard is not recommended for children under the age of 12 years. Page 2 of 13 ELDERLY POPULATION The elderly are at increased risk of serious consequences of adverse reactions. If an NSAID is considered necessary, the lowest effective dose should be used and for the shortest possible duration. The patient should be monitored regularly for GI bleeding during NSAID therapy. If renal or hepatic function is impaired, dosage should be assessed individually. _Renal impairment _ Caution s Read the complete document